2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: Identification, stereochemistry and initial SAR

Paul G Wyatt; Michael J Allen; Alan D Borthwick; Dave E Davies; Anne M Exall; Richard J D Hatley; Wendy R Irving; David G Livermore; Neil D Miller; Fabrizio Nerozzi; Steve L Sollis; Anna Katrin Szardenings

doi:10.1016/j.bmcl.2005.03.045

2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: Identification, stereochemistry and initial SAR

Bioorg Med Chem Lett. 2005 May 16;15(10):2579-82. doi: 10.1016/j.bmcl.2005.03.045.

Authors

Paul G Wyatt¹, Michael J Allen, Alan D Borthwick, Dave E Davies, Anne M Exall, Richard J D Hatley, Wendy R Irving, David G Livermore, Neil D Miller, Fabrizio Nerozzi, Steve L Sollis, Anna Katrin Szardenings

Affiliation

¹ Department of Medicinal Chemistry CVU UK, GlaxoSmithKline Research and Development Limited, Medicines Research Centre, Gunnels Wood Road, Stevenage, Herts SG1 2NY, UK.

PMID: 15863320
DOI: 10.1016/j.bmcl.2005.03.045

Abstract

This paper covers efforts to discover orally active potent and selective oxytocin antagonists. Screening pooled libraries identified a novel series of 2,5-diketopiperazine derivatives with antagonist activity at the human oxytocin receptor. We report the initial structure-activity relationship investigations and the determination of the stereochemistry of the most potent compounds.

MeSH terms

Humans
Piperazines / chemistry*
Piperazines / pharmacology*
Receptors, Oxytocin / antagonists & inhibitors*
Stereoisomerism
Structure-Activity Relationship

Substances

Piperazines
Receptors, Oxytocin